AKT1 and cancer: Counteracting FGF21 overexpression through knockdown techniques or the use of neutralising antibodies can restore the balance in the AKT-mTORC1 signalling pathway and reduce cholesterol accumulation in CD8+ T cells, resulting in the enhanced anti-cancer ability of T cells and markedly reduced tumour growth.7